Plp1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| PLP1 Protein | |
|---|---|
| Protein Name | Proteolipid Protein 1 (PLP) / Myelin Proteolipid |
| Gene | PLP1 |
| UniProt ID | P60228 |
| Molecular Weight | ~30 kDa (PLP), ~25 kDa (DM20 isoform) |
| Subcellular Localization | Myelin sheath, oligodendrocyte plasma membrane |
| Protein Family | Proteolipid protein family |
PLP1 encodes proteolipid protein 1 (PLP), the most abundant protein in central nervous system myelin[1]. PLP and its alternatively spliced isoform DM20 are integral membrane proteins that are essential for the formation, stability, and maintenance of the myelin sheath[2]. Mutations in PLP1 cause severe demyelinating disorders including Pelizaeus-Merzbacher disease (PMD). PLP constitutes approximately 50% of total myelin protein and forms the major structural protein of CNS myelin[1:1].
PLP1 is an extremely hydrophobic protein with four transmembrane domains:
| Domain | Residues | Function |
|---|---|---|
| N-terminal | 1-30 | Cytoplasmic, myristoylation site |
| TM1 | 31-59 | First transmembrane helix |
| Loop A | 60-89 | Extracellular loop |
| TM2 | 90-116 | Second transmembrane helix |
| Loop B | 117-147 | Cytoplasmic loop |
| TM3 | 148-176 | Third transmembrane helix |
| Loop C | 177-200 | Extracellular loop |
| TM4 | 201-231 | Fourth transmembrane helix |
| C-terminal | 232-276 | Cytoplasmic tail |
PLP1 is essential for multiple aspects of CNS myelination:
X-linked recessive disorder caused by PLP1 mutations[3]:
Clinical Forms:
| Type | Severity | Onset |
|---|---|---|
| Connatal | Severe | Birth-early infancy |
| Classic | Moderate | infancy-childhood |
| Null | Severe/lethal | Neonatal |
Pathogenesis:
| Approach | Status | Details |
|---|---|---|
| Gene therapy | Clinical trials | AAV-PLP1 delivery |
| Cell therapy | Preclinical | Oligodendrocyte transplantation |
| Small molecules | Research | Myelin-enhancing compounds |
| Symptomatic | Approved | Seizure control, spasticity |
The study of Plp1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Greer JM, et al. Proteolipid protein: function and structure. J Neurochem. 2007;103(1):1-10. PMID:17623052 ↩︎ ↩︎ ↩︎
Inoue K. PLP1-related disorders. Brain Dev. 2009;31(7):511-519. PMID:19328782 ↩︎
Hobson GM, et al. PLP1 mutations in Pelizaeus-Merzbacher disease. Hum Mutat. 2006;27(11):1065-1069. PMID:16941468 ↩︎